Vertex Pharmaceuticals Inc (VRTX) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.

Total Revenue Chart for Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc (VRTX) revenue for FY2025 was USD 12.1B, a 9.6% change from FY2024. Vertex Pharmaceuticals Inc's revenue grew from USD 2.3M in 1990 to USD 12.1B in 2025 (524882.6% over 35 years). Earnings per share moved from USD -3.77 in 2010 to USD 12.82 in 2022. Revenue compound annual growth rate: 5-year CAGR of 14.2%, 10-year CAGR of 27.9%, 20-year CAGR of 24.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$141.65B
Implied Share Price
$558.88
Enterprise Value
$135.78B
Revenue (TTM)
$12.59B
EBITDA
$5.10B
Profit Margin
35.00%
Trailing P/E
32.55
Forward P/E
26.39
Price/Book (MRQ)
7.00
Price/Sales (TTM)
11.25
EV/EBITDA
26.62
EV/Revenue
10.79
Dividend Yield
—
Book Value
$79.92
Free Cash Flow (FY2025)
$3.19B
Free Cash Flow Yield
2.25%

Snapshot as of 1st November 2026 — not point-in-time controlled, may lag the live market by a few days.